Alpha 2.0
Login Register
» Authors » Maximilian Hochmair

Maximilian Hochmair

Explore the profile of Maximilian Hochmair including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 1071
Followers 0
Related Specialties
Oncology
General Medicine
Radiology
Top 10 Co-Authors
Gerhard Hamilton
Barbara Rath
Adelina Plangger
Robert Zeillinger
Christoph Weinlinger
Dagmar Krenbek
Lucian Beer
Hannah Fabikan
Helmut Prosch
Lukas Klameth
Published In
Wien Klin Wochenschr
Lung Cancer
Anticancer Drugs
N Engl J Med
J Thorac Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
Janne P, Wang B, Cho B, Zhao J, Li J, Hochmair M, et al.
J Clin Oncol . 2025 Jan; :JCO2401269. PMID: 39879577
Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III...
2.
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Skoulidis F, Li B, Hochmair M, Govindan R, Vincent M, van der Wekken A, et al.
Oncologist . 2025 Jan; 30(1). PMID: 39846981
Introduction: We describe the safety of sotorasib monotherapy in patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) and discuss practical recommendations for managing key risks. Methods: Incidence rates...
3.
Characterization of a pleomorphic rhabdomyosarcoma cell line
Stickler S, Lang C, Rieche M, Eggerstorfer M, Hohenegger M, Hochmair M, et al.
Sci Rep . 2025 Jan; 15(1):2893. PMID: 39843506
Pleomorphic rhabdomyosarcoma (PRMS) is an extremely rare soft tissue tumor with dismal prognosis that has a higher incidence in adults compared to the other RMS subtypes. The unique PRMS cell...
4.
Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis
Ay L, Steiner D, Fabikan H, Illini O, Krenbek D, Klikovits T, et al.
Lung Cancer . 2024 Nov; 198:107997. PMID: 39486111
Background: Phase 3 trials of neoadjuvant immunotherapy-based regimens have shown promising outcomes in patients with resectable non-small cell lung cancer (NSCLC). However, real-world data on treatment regimens with combined chemoimmunotherapy,...
5.
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Hochmair M, Schenker M, Cobo Dols M, Kim T, Ozyilkan O, Smagina M, et al.
J Thorac Oncol . 2024 Oct; 20(2):203-218. PMID: 39477187
Introduction: Poly (adenosine diphosphate-ribose) polymerase inhibitors can up-regulate programmed cell death-ligand 1 expression and promote immune-mediated responses and may improve efficacy of first-line anti‒programmed cell death protein 1‒based therapies in...
6.
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Wolf J, Hochmair M, Han J, Reguart N, Souquet P, Smit E, et al.
Lancet Oncol . 2024 Oct; 25(10):1357-1370. PMID: 39362249
Background: Capmatinib has previously shown activity in treatment-naive and previously treated patients with non-small-cell lung cancer (NSCLC) and a MET exon 14-skipping mutation (METex14). Here, we report the final outcomes...
7.
Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study
Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F, et al.
Lung Cancer . 2024 Sep; 196:107924. PMID: 39306923
Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche/Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I/III trial of first-line atezolizumab or placebo plus carboplatin/etoposide in...
8.
Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study
Hochmair M, Terbuch A, Lang D, Trockenbacher C, Augustin F, Ghanim B, et al.
Cancers (Basel) . 2024 Jul; 16(14). PMID: 39061224
This was a retrospective study of the profile and initial treatments of adults diagnosed with early-stage (ES) non-small cell lung cancer (NSCLC) during January 2018-December 2021 at 16 leading hospital...
9.
The Landsteiner lung cancer research platform (LALUCA) : Objectives, methodology and implementation of a real-world clinical lung cancer registry
Lang-Stoberl A, Fabikan H, Hochmair M, Kirchbacher K, Rodriguez V, Ay L, et al.
Wien Klin Wochenschr . 2024 Apr; PMID: 38652311
Background: Lung cancer is a major health burden in Austria; however, limited real-world data exist on the diagnostic and treatment reality of lung cancer patients in Austria. The collection of...
10.
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer
Wu Y, Dziadziuszko R, Ahn J, Barlesi F, Nishio M, Lee D, et al.
N Engl J Med . 2024 Apr; 390(14):1265-1276. PMID: 38598794
Background: Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, -positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy...